Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Libtayo was a late entrant into the PD-1/PD-L1 inhibitor market and while it has been able to carve out a small niche in cutaneous squamous cell carcinoma (CSCC), another form of skin cancer ...

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...

Race, age, and sex were predictors of survival in patients with SCC of the upper esophagus, highlighting the need to address disparities in esophageal SCC management.

National Cancer Institute, Bethesda, Maryland, USA Background: Oesophageal squamous cell carcinoma (OSCC) has a very poor prognosis, which is largely due to late diagnosis. Successful early detection ...

Skin cancer often causes itching. Itching is more common with basal cell carcinoma and squamous cell carcinoma. Itching is less common with melanoma but may still be a symptom. Liver, Bile Duct, ...

AC will not go away on its own. While it may not look like much in its very early stages, it is serious and requires diagnosis and treatment because it can progress to squamous cell carcinoma. If you ...